Proceedings | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.

BPS September 2015


Selective peptidic activators for protein phosphatase-1

Maja Kohn

Principal Investigator, European Molecular Biology Laboratory

COMPANY DESCRIPTION

Protein serine/threonine phosphatases (PSTPs) are considered undruggable due to their conserved catalytic site and broad substrate specificity. Protein phosphatase-1 (PP1) is a ubiquitous PSTP that is predicted to catalyze a majority of Ser and Thr dephosphorylations in eukaryotic cells. PP1 has broad substrate specificity but is restrained in vivo by numerous PP1-interacting proteins functioning for example as substrate-targeting proteins and forming specific holoenzymes with PP1. PP1 holoenzymes play a role in many different diseases such as cancer (counteracting oncogenic kinases), diabetes (insulin release) and HIV (viral translation). We recently developed the first compound, a peptide, that selectively activates PP1 in intact cells by disrupting protein-protein interactions of PP1 and its regulatory proteins. The activator does not act on the most closely related protein phosphatases 2A and 2B. I will introduce the PP1-disrupting peptides including applications such as counteracting oncogenic kinase signaling.


s2Member®
loading...